

-----Original Message-----

From: 5.1.2e <5.1.2e@5.1.2e>

Sent: Wednesday, November 4, 2020 4:09 PM

To: 5.1.2e <5.1.2e@5.1.2e>, (5.1.2e) <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>

<5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>

<5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>

<5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>

5.1.2e <5.1.2e@5.1.2e>

Subject: Tweede revisie sterfte paper (FW: Your EID MS # EID-20-2999.R1)

Beste allen,

Eindelijk weer nieuws van EID over het sterfte manuscript.

Er zijn nog wat revisies gewenst, zie onder. Daarna horen we pas of het wel of niet wordt geaccepteerd.

Ik denk dat ze meevallen (voor zolang ze binnen de maximale woordcount passen anders wordt het nog creatief gepiel..).

Jullie horen van me als ik het weer revised heb.

Groeten

5.1.2e

-----Original Message-----

From: Emerging Infectious Diseases <5.1.2e@manuscriptcentral.com>

Sent: woensdag 4 november 2020 15:34

To: 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>, 5.1.2e <5.1.2e@5.1.2e>

Subject: Your EID MS # EID-20-2999.R1

04-Nov-2020

Dear 5.1.2e:

Thank you for submitting a revised version of your manuscript "Monitoring excess mortality during epidemics of influenza and COVID-19 and estimating the SARS-CoV-2 infection fatality rate in the Netherlands." Although the topic is still of interest, the manuscript will need further revising before it can be considered for publication in Emerging Infectious Diseases. The reviewers rate the revision as sufficiently improved over the original that we invite a second revision that incorporates the suggestions for further improvement (below). We look forward to considering a revised manuscript that takes these suggestions into account.

Please keep in mind that sending a revised version of this manuscript does not guarantee acceptance.

The revised manuscript should be accompanied by a letter addressing each of the reviewers' suggestions item by item. If you wish to reject any suggestion, please state your reasons. Please submit the revised manuscript no later than 4 weeks from today.

Please submit your revised manuscript to EID Manuscript Central. Do not send your revision by email. To submit your revised manuscript, log in to Manuscript Central at <http://mc.manuscriptcentral.com/eid>. In your Author Center click onto Manuscripts with Decisions. When you click onto that you will see your manuscript. On the right-hand side of the screen is a link for 'create a revision'. Click onto that link and follow the steps to submit your revised manuscript.

Please note that your revised manuscript must still meet the submission requirements for the type of article you're submitting, including word count, references and figure and table limits. Additional information on submission guidelines is available at www.cdc.gov/eid.

Thank you for your interest in our journal.

5.1.2e

Emerging Infectious Diseases

5.1.2e <5.1.2e@cdc.gov>

(phone)

5.1.2e (fax)

Reviewer: 2

Comments to the Author

Thank you to the authors for suitably revising the manuscript per reviewer comments. This manuscript clearly identifies the objective of presenting excess mortality due to influenza and COVID-19 and comparing the severity of the two and clearly outlines the methods used.

I have just a few additional comments below.

5.1.2i



5.1.2i

Reviewer: 1

Comments to the Author

The authors have addressed all of my comments and suggestions.

Minor point: the numbers on the x axis of Figs. 1 and 2 seem to be showing some sort of code associated with each date instead of the actual dates.

Reviewer: 3

Comments to the Author

I am happy with the additional explanations of the methods.